Critical Contrast: Corium International (CORI) vs. Its Peers

Corium International (NASDAQ: CORI) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Corium International to related companies based on the strength of its valuation, dividends, profitability, analyst recommendations, earnings, risk and institutional ownership.

Volatility & Risk

Corium International has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Corium International’s competitors have a beta of 37.20, indicating that their average stock price is 3,620% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Corium International and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corium International 0 0 7 0 3.00
Corium International Competitors 884 3841 6817 181 2.54

Corium International presently has a consensus target price of $13.50, indicating a potential upside of 30.94%. As a group, “Pharmaceuticals” companies have a potential upside of 18.74%. Given Corium International’s stronger consensus rating and higher possible upside, equities analysts clearly believe Corium International is more favorable than its competitors.

Profitability

This table compares Corium International and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corium International -149.99% -612.73% -64.69%
Corium International Competitors -2,435.14% -66.75% -8.28%

Valuation & Earnings

This table compares Corium International and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Corium International $31.86 million -$47.79 million -6.17
Corium International Competitors $8.17 billion $1.09 billion 129.80

Corium International’s competitors have higher revenue and earnings than Corium International. Corium International is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

89.4% of Corium International shares are held by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceuticals” companies are held by institutional investors. 46.5% of Corium International shares are held by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Corium International competitors beat Corium International on 7 of the 13 factors compared.

Corium International Company Profile

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit